Search

You searched for "GMC"

88 results found

Imaging and surveillance in sporadic renal angiomyolipoma: how and when to monitor effectively

4 March 2025 | | URO - Urologic Oncology
Renal angiomyolipoma (AML) are benign tumours, accounting for approximately 2–3% of all renal neoplasms [1]. Seventy percent of renal AMLs are sporadic, and 20–30% are associated with genetic aetiology. They are composed of smooth muscle, blood vessels, and adipose tissue....

Artificial intelligence in bladder cancer diagnostics

2 May 2025 | | URO - Urologic Oncology
Bladder cancer (BCa), ranking as the 10th most common cancer worldwide, poses a significant health burden with high morbidity and mortality [1]. Timely tumour detection and accurate evaluation are crucial for effective management, as the prognosis is dependent on the...

Update on immunotherapy for non-muscle invasive transitional cell carcinoma of the bladder

7 January 2021 | | URO - Urologic Oncology
Patients with high-risk non-muscle invasive bladder cancer (NMIBC) that have failed Bacillus Calmette-Guérin (BCG) treatment are a difficult group to treat, and many may not be suitable for the preferred treatment option of radical cystectomy. Bladder-preserving treatments for BCG-unresponsive high-risk...

Enhancing performance and wellbeing for surgeons: the science of life coaching

3 September 2024 | | URO - Andrology, URO - Basic Science Research, URO - Endourology & Stones, URO - Infection, URO - Neurourology, URO - Paediatric Urology, URO - Core Urology, URO - Functional / Reconstructive Urology, URO - Technology, URO - Trauma & Emergency, URO - Urologic Oncology, URO - Uroradiology
Life coaching has emerged as a powerful personal and professional development tool, particularly for individuals navigating high-stakes environments. Life coaching emphasises self-awareness, self-management and self-efficacy, including establishing desired outcomes, goal setting and developing skills and action plans to achieve them....

Biomarkers in prostate cancer detection

1 July 2018 | | URO - Basic Science Research, URO - Urologic Oncology, URO - Technology
Prostate cancer (PCa) is the second most common cancer in men with an estimated prevalence of 1.1 million worldwide in 2012. This heterogeneous disease resulted in approximately 307,000 deaths, making it the fifth leading cause of cancer-related death in men...

Inpatient care of patients with established spinal cord injury - what a general urologist needs to know

1 January 2014 | | URO - Trauma & Emergency, URO - Neurourology
Introduction Spinal cord injury (SCI) is a devastating, life-changing condition, which is currently irreversible. Depending on the level of the spinal cord affected (and whether the lesion is complete or incomplete), patients may subsequently develop reduced voluntary motor function, sensory...

Mechanisms and prevention of catheterisation associated urethral injury (CAUI)

5 November 2019 | | URO - Neurourology, URO - Infection, URO - Functional / Reconstructive Urology, URO - Technology
Urethral catheterisation is a common procedure performed by health professionals across different grades and specialties in a variety of clinical settings. An estimated 15-25% of hospitalised patients have a urinary catheter inserted during their inpatient stay and up to 13%...

Pyonephrosis: is the kidney always doomed?

9 March 2020 | | URO - Endourology & Stones
Pyonephrosis (Greek pyon ‘pus’ + nephros ‘kidney’) is defined in Campbell-Walsh Urology [1] as an infected hydro-nephrosis associated with suppurative destruction of the renal parenchyma which results in total or near total loss of renal function. The true incidence of...

Intravesical GAG replacement therapies for bladder pain syndrome / interstitial cystitis – an update

4 May 2020 | | URO - Functional / Reconstructive Urology, URO - Infection, URO - Basic Science Research
The barrier function of the glycosaminoglycan (GAG) layer of the urothelium was identified by Parsons in 1975, and intravesical therapies to treat chronic inflammatory conditions of the bladder were developed soon after. However, the active role of the urothelium in...

Trials offering cytoreductive surgery for men with de novo synchronous metastatic prostate cancer

8 November 2021 | | URO - Basic Science Research, URO - Urologic Oncology
Life expectancy in men diagnosed with de novo synchronous metastatic hormone-sensitive prostate cancer (mHSPC) has risen to a median of 4.8 years with upfront systemic agents (such as docetaxel) in addition to standard androgen deprivation therapy (ADT) [1-3]. Within this...

Men with a susceptibility to prostate cancer: implications of ethnicity in PCa risk-prediction and diagnosis

5 January 2022 | | URO - Urologic Oncology
The diagnostic and therapeutic landscapes of prostate cancer (PCa) have advanced at great pace in the past decade. However, disparities in access to care, clinical outcomes and representation in therapeutic, interventional and genomic studies continue to exist between Afro-Caribbean (AC)...

The doctor as the patient: receiving bad news

13 March 2023 | URO - Urologic Oncology
This article, written by a GP working in the NHS, gives a unique insight into the experience of being a urology patient and some thoughtful advice on ‘breaking bad news’. Day 1 Alarm bells ring. It’s spotting an email from...